Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

The world's largest contract research organization, Quintiles Transnational has been operating in Asia-Pacific for more than 17 years. Two Asia-based executives, Quintiles India CEO Dr. Ferzaan Engineer and Senior VP and Head of Clinical Development for Quintiles Asia-Pacific Dr. Mr. Tharmaratnam recently shared their views with PharmAsia News on the changing CRO landscape in Asia. In part one of the interview, they talked about clinical research and development trends in the region, and opportunities and challenges for multinational CROs operating in China.

You may also be interested in...



Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines

TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule

Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines

TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule

Change Of Guard At Quintiles India As Company Continues Aggressive Asia Efforts With Samsung Deal

MUMBAI - Quintiles Transnational Corp.'s India CEO Ferzaan Engineer will step down after serving the multinational contract research organization since its inception in India more than 13 years ago

Related Content

UsernamePublicRestriction

Register

SC073042

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel